Protein C News and Research

RSS

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Treating critically ill COVID-19 patients with non-altered umbilical cord stem cells increases survival

Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.

8 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021

Immunomodulatory therapies for nephrological autoimmune diseases may help treat severe COVID-19

Various viruses and bacteria have long been known to cause autoimmune diseases where there is such a predisposition. This phenomenon also seems to play a major role in SARS-CoV-2, especially in severe courses.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

New chip mimicking bovine endometrium could play key role in cattle’s pregnancy success

To investigate factors that can jeopardize pregnancy success in cattle, researchers at the University of São Paulo (USP) in Brazil used a kind of chip to mimic the environment of the endometrium, the tissue that lines the inside of the uterus.

8 Jun 2021

Study confirms the importance of low-protein, high-carbohydrate diet

Researchers at the University of Sydney's Charles Perkins Centre conducted the largest ever study of nutrient interactions by examining the health of mice on 33 different diets containing various combinations of protein to carbs, and different sources of carbohydrate.

8 Jun 2021

Fluorescence-based assay for detecting SARS-CoV-2 neutralizing antibodies

Researchers have developed a rapid assay to rapidly detect neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an imaging technique they developed for the Ebola virus.

8 Jun 2021

Study offers a deeper understanding of the molecular basis for schizophrenia

A study conducted by a group of Brazilian researchers contributes to a deeper understanding of the molecular basis for schizophrenia, and potentially to the development of more specific and effective treatments for the disease.

8 Jun 2021

New blood test helps monitor patient’s response to cancer treatment

Cancer patients who are undergoing targeted therapy can look forward to a new blood test that could tell their doctors whether the treatment is working, within one day after the start of the treatment.

8 Jun 2021

New drug shows promise against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

8 Jun 2021

Distinct spike protein mutations in SARS-CoV-2 variant in Russia

Additionally, a novel variant has recently been characterized by researchers from Russia in the journal Viruses. The variant, first discovered in January 2021 in Northwest Russia, is characterized by distinct spike protein mutations.

7 Jun 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

Oral antidiabetic medication provides kidney protection in focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare form of kidney inflammation (glomerulonephritis) in which the glomeruli become increasingly scarred (sclerotic), leading to progressive loss of kidney function.

7 Jun 2021

Study reveals mechanism through which 'good' viruses can attack 'bad' bacteria

The battle against antibiotic-resistant bacteria: A new study at Tel Aviv University revealed a mechanism through which "good" viruses can attack the systems of "bad" bacteria, destroy them and block their reproduction.

7 Jun 2021

Study uncovers novel molecular mechanism of immune cell migration

In a new study, researchers from Osaka University discovered a novel molecular mechanism by which immune cells migrate to fight off infections. These findings may help in understanding the development of certain immune deficiency disorders and establish novel therapies against them.

7 Jun 2021

New research identifies protein as therapeutic anti-viral target for COVID-19

New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target.

7 Jun 2021